Introduction {#Sec1}
============

*Fusobacterium nucleatum* is a Gram-negative facultative anaerobic bacillus that is a normal component of the oral microbiome. It has been associated with periodontal diseases^[@CR1]^ as well as malignancies of the oral cavity, head and neck, oesophagus, cervix, stomach and colon^[@CR2]--[@CR4]^. This association with a range of malignancies has led to its referral as an "oncobacterium"^[@CR4]^. In these diseases, *F. nucleatum* biofilms have been demonstrated to play a critical role.

Chronic periodontitis results from a dysbiosis in subgingival plaque biofilm communities that leads to the emergence of pathogenic species that dysregulate the host immune response leading to sustained and uncontrolled inflammation^[@CR5],[@CR6]^. In chronic periodontitis, *F. nucleatum* has been shown to act as a backbone for pathogenic subgingival polymicrobial biofilms by forming a bridge between the more commensal early colonisers and the more pathogenic late colonisers^[@CR1],[@CR7],[@CR8]^. This microbial biofilm is therefore responsible for the initiation and progression of chronic periodontitis^[@CR9],[@CR10]^. Apart from their role in periodontitis, bacterial biofilms and microbiota organisation have also been associated with gut tumours^[@CR11]^. In colorectal cancer, *Fusobacterium* has been demonstrated to be intimately involved in modulating the tumour immune microenvironment and recruiting myeloid cells that assist in tumorigenesis, tumour cell proliferation and metastasis^[@CR12]^, modulating autophagy and resistance to chemotherapies^[@CR13]^.

Current treatment of periodontal disease is mechanical debridement with antibiotics and antiseptics as adjuncts. However, this approach is not without controversy^[@CR14]^, with the development of antibiotic resistance being a major caveat^[@CR15]^, along with dysbiosis of oral microbiota contributing to inflammation and disease recurrence^[@CR16],[@CR17]^. Current treatment of colorectal cancer includes surgery, chemotherapy and radiation therapy. In both cases, a targeted therapy that specifically attacks *Fusobacterium* in biofilms can potentially provide a new modality to combat these important diseases. Optimal treatment of biofilms in periodontitis and colorectal cancer would target specific bacteria in the biofilms, have minimal inflammatory effect, and a low risk for resistance development by bacteria.

Alternatives to antibiotics that have a narrow range in their bacterial targets, and capable of breaking down bacterial biofilms are bacteriophages^[@CR18],[@CR19]^. Bacteriophages, which can be either lytic or temperate^[@CR20]^, have been involved in an evolutionary arms race with bacteria, and as such are capable of overcoming or adapting to development of bacterial resistance against them^[@CR21]^. Temperate bacteriophages are present in bacteria in a latent phase until certain conditions leading to bacterial cellular damage occurs e.g. exposure to ultra-violet radiation. Lytic bacteriophages, on the other hand, will lyse bacteria after infection and have potential for therapeutic use^[@CR20]^. *F. nucleatum* is an important micro-organism in the structural composition of biofilms in periodontitis and colon cancer and as such provides a useful target for bacteriophages. To date, however, only temperate bacteriophages of *F. nucleatum*, ɸFunu1 and ɸFunu2, have been fully characterised^[@CR22]^. There has been a single report of a lytic bacteriophage against *F. nucleatum*, Fnpɸ02 that has been isolated and phenotypically characterised^[@CR23]^. Full genomic characterisation was not performed, and short amplicons within Fnpɸ02 showed homology ranging from 84% to 98% to *Cutibacterium acnes* (formally *Propionibacterium acnes*) bacteriophages. The genes where these amplicons were taken are highly conserved in *C. acnes* bacteriophages. *C. acnes* has been isolated frequently with *F. nucleatum*^[@CR24]^ but no bacteriophages have been found that target both *F. nucleatum* and *C. acnes*.

Bacteriophages lytic against other types of bacteria such as *Pseudomonas aeruginosa*^[@CR25]^, *Escherichia coli*^[@CR26]^ and *Streptococcus mutans*^[@CR27]^ have been shown to be able to disrupt mono-biofilms formed by their respective hosts. The potential exists for use of bacteriophages against biofilms in periodontal infection^[@CR18],[@CR19]^ and colon cancer. We describe here the full genomic and morphological characterisation of a novel lytic bacteriophage, FNU1, which is capable of disrupting existing *F. nucleatum* biofilms. This bacteriophage has a novel genome (NCBI Genbank Accession Number: MK554696), with little homology to other viruses, and offers the potential for development to prevent and treat *F. nucleatum*-associated oral disease and cancers.

Methods {#Sec2}
=======

Ethics {#Sec3}
------

All methods were performed in accordance with the La Trobe University Ethics, Biosafety and Integrity guidelines and regulations. Informed consent was obtained from participants for their involvement and use of samples in this study. The study protocols were approved by the La Trobe University Ethics Committee, reference number: S17-112.

*Fusobacterium nucleatum* bacterial growth conditions {#Sec4}
-----------------------------------------------------

*Fusobacterium nucleatum* (ATCC 10953) that had been completely characterised^[@CR28]^ and previously studied in a polymicrobial biofilm^[@CR29]^ was used for all experiments. The cultures were grown in brain heart infusion media (BHI; Oxoid, Australia) supplemented with 0.5% cysteine (Sigma, Australia) and 0.5% haemin (Sigma, Australia) in either broth or agar. The cultures were grown anaerobically using anaerobic generating packs (AnaeroGen) (Oxoid, Australia) at 37 °C. For this study, the identity of the strain was confirmed using 16 S rRNA gene amplification and sequencing via U27F: 5′AGAGTTTGATCMTGGCTCAG3′ and U1492R: 5′AAGGAGGTGWTCCARCC 3′ primers^[@CR30]^. The thermocycling conditions were 95 °C for 3 minutes, 32 cycles of 95 °C for 30 seconds, 60 °C for 30 seconds, and 72 °C for 90 seconds, with a final extension at 72 °C for 10 minutes. The amplicons were cleaned using QIAquick^®^ PCR purification kits (Qiagen, Australia) and analysed by Sanger sequencing at the Australian Genome Research Facility (AGRF) in Queensland, Australia.

Bacteriophage isolation {#Sec5}
-----------------------

Mouthwash samples were collected from dental practices in Bendigo (Victoria, Australia) and screened for the presence of lytic bacteriophages against *F. nucleatum* using the enrichment method in BHI broth according to Gill and Hyman^[@CR31]^. Briefly, 100 µL of *F. nucleatum* grown previously in broth culture for 48 hours anaerobically was added to 1 mL of sample and 20 mL of broth and incubated anaerobically at 37 °C for seven days. The enrichment was filtered using a 0.20 µm cellulose acetate filter (Microanalytix, Australia) before spotting 10 µL of the filtrate on a freshly prepared lawn of *F. nucleatum* on 1% agar. The plate was incubated for 48 hours anaerobically at 37 °C. Observed plaques were excised and purified as described previously^[@CR32]^. To test the host range of the purified bacteriophage, it was also spotted onto cultures of *Streptococcus mutans, Porphyromonas gingivalis* and *C. acnes*, which are all found in the oral cavity.

Electron microscopy {#Sec6}
-------------------

The purified bacteriophage particles were visualised using a JEOL JEM-2100 Transmission Electron Microscope (TEM) using 400-mesh carbon-coated copper grids (ProSciTech, Australia). The bacteriophage lysate was allowed to adsorb to the grid for 30 seconds before being washed with Milli-Q® water (Promega, Australia). The adsorbed particles were then negatively stained twice for 30 seconds with 2% \[W/V\] uranyl acetate (Sigma, Australia). Excess stain on the grids was removed using filter paper before being air dried for 20 minutes. The grid was visualised and images captured with a Gatan Orius SC200D 1 wide-angle camera (Gatan Microscopy Suite and Digital Micrograph Imaging software version 2.3.2.888.0) at 200 kV. Further image analysis was achieved in ImageJ software version 1.8.0_112.

DNA extraction {#Sec7}
--------------

Bacteriophage DNA was extracted from a highly concentrated purified lysate (approximately 10^11^ PFU mL^−1^) using the phenol-chloroform method as previously described^[@CR32]^. All compounds used in the DNA extraction process were obtained from Sigma-Aldrich (Australia) unless stated otherwise. The concentrated bacteriophage stock was treated with 5 mmol L^−1^ of MgCl~2~ and 1.0 µL each of RNase A (Promega, Australia) and DNase I (Promega, Australia) to a final concentration of 10 µg mL^−1^. The solution was incubated at room temperature for 30 minutes to digest extraneous DNA or RNA. Polyethylene glycol 8000 (PEG) at 10% \[W/V\] and sodium chloride (NaCl at 1 g L^−1^) were added to the mixture and incubated overnight. The solution was centrifuged at 12000 × *g* for 5 minutes and pellets resuspended in 50 µL nuclease-free water (Promega, Australia). Bacteriophage proteins were digested by the addition of Proteinase K (50 µg mL^−1^), EDTA (20 mmol L^−1^) and sodium dodecyl sulphate (0.5% (v/v)) and incubating for one hour at 55 °C. An equal volume of phenol-chloroform-isoamyl alcohol (29:28:1) was then added to separate viral DNA from proteins. The mixture was gently vortexed and then centrifuged at 12000 × *g* for 10 minutes to isolate the aqueous phase. DNA was precipitated by adding an equal volume of isopropanol and incubating overnight at −20 °C. The DNA pellet was collected by centrifugation at 12000 × *g* for 5 minutes. The DNA pellet was washed in 70% ethanol, air-dried and finally resuspended in 30 µL of nuclease-free water (Promega, Australia).

Whole genome sequencing and *in-silico* analysis {#Sec8}
------------------------------------------------

Nextera® XT DNA sample preparation kits were used to prepare DNA libraries according to the manufacturer's instructions (Illumina, Australia). The libraries were sequenced on an Illumina MiSeq® using a MiSeq® V2 reagent kit (300 cycles) with 150 basepair (bp) paired end reads. Sequence reads were assembled *de novo* using Geneious software version 11.0.5. Gene prediction was achieved by predicting open reading frames (ORFs) using ATG, GTG, and TTG start codons with a minimum nucleotide length of 50 bp. The ORFs were translated using Geneious and analysed by BLASTP (<https://blast.ncbi.nlm.nih.gov/>) to ascribe potential function. The genome was further examined for the presence of transfer RNA (tRNA) and transfer-messenger RNA (tmRNA) using ARAGORN^[@CR33]^ and tRNAscan-SE 2.0^[@CR34]^. Whole genome alignments and phylogenetic tree construction were performed in CLC genomics workbench version 9.5.4 by UPGMA algorithm with 1,000 replicate bootstrapping. The alignment included whole genomes of FNU1 and other bacteriophages specific for oral bacteria obtained from the NCBI Genbank.

Biofilm growth and quantification {#Sec9}
---------------------------------

Biofilm experiments were conducted anaerobically using BHI broth (Oxoid, Australia) supplemented with 0.5% cysteine, 0.5% haemin and 0.5% glucose in 96 well polystyrene plates (Greiner bio-one, Australia) coated with 0.5% gelatin. *F. nucleatum* was cultured for 48 hours and 100 µL of approximately 1 × 10^8^ CFU mL^−1^ of *F. nucleatum* in exponential growth phase was added to each well before an equal volume of broth was added. The inoculated plates were incubated at 37 °C under anaerobic conditions and shaking at 120 rpm (Ratek Medium Orbital shaking incubator) for 4 days with sterile broth replenishment after 48 hours. To each well, 10 µL of bacteriophage FNU1 at 10^11^ PFU/mL was added after 4 days of biofilm formation. The biofilms were then incubated for a further 24 hours anaerobically at 37 °C before quantification assays completed as described previously^[@CR35]^. Briefly, planktonic cells were washed off gently using MilliQ® deionised water (Merck, Australia) and the attached cells air dried. The attached biomass was then stained with 200 µL of 0.1% crystal violet for 5 minutes, washed using deionised water and air-dried for 5 minutes. An equal volume of ethanol (70%) was added to each well to decolourise the stained attached cells and the absorbance of the crystal-violet stained ethanol was evaluated at a wavelength of 600 nm (OD~600~) using a FlexStation 3 plate reader (Molecular Devices, United States).

Biofilm viability analysis {#Sec10}
--------------------------

To test for viability, the *F. nucleatum* biofilm was grown on gelatin-coated microscope slides in the same manner as in the 96 well plates described above. SYBR gold® and Propidium Iodide (PI) were used to stain nucleic acids of live (membrane intact) and dead (membrane compromised) cells, respectively. Propidium Iodide (3 µL) was added to 100 µL of SYBR gold ® diluted (1:100) in dimethyl sulfoxide (Sigma, Australia). The mixture was applied to the biofilm on slides and incubated for 30 minutes. Excess PI and SYBR gold ® were rinsed off and slides air-dried before mounting with 5 µL Vectorshield® (Burlingame, USA) and coverslips. The slides were examined using an Olympus Fluoview Fv10i-confocal laser-scanning microscope (Olympus Life Science, Australia) with excitation wavelength at 485 nm. Green emission at fluorescence 535 nm and Red emission at fluorescence 635 nm were measured to indicate live versus dead cells on the slides.

Statistical analysis {#Sec11}
--------------------

The absorbance values quantifying the biofilms were analysed for normality using the Shapiro Wilk test and the medians compared by a paired T-test. The p-values of less than 0.05 were considered statistically significant. All statistical analysis was performed using the Statistical Package for Social Sciences (SPSS version 25).

Results {#Sec12}
=======

Isolation and phenotypic characterisation of *F. nucleatum* bacteriophage FNU1 {#Sec13}
------------------------------------------------------------------------------

One mouthwash sample was found to produce clear plaques on 1% BHI agar. This was not observed on BHI with 1.5% agar. On the less concentrated 1% agar, clear round plaques of approximately 1 mm diameter were seen (Fig. [1A](#Fig1){ref-type="fig"}). The host range of FNU1 was restricted to *F. nucleatum*, and did not extend to other bacteria found in the oral cavity that we tested. TEM revealed a *Siphoviridae* bacteriophage with an icosahedral head of ≈88 nm in diameter and a long flexible tail terminating in a spike (Fig. [1B](#Fig1){ref-type="fig"}). The tail was approximately 310 nm long and ≈10 nm wide with a spike at the end, measuring an average of ≈20 nm long and ≈5 nm wide on the widest section.Figure 1(**A**) Bacteriophage FNU1 spotted onto *F. nucleatum* culture on BHI with 1% agar. From the top left to the bottom right, each square represents a 10-fold serial dilution of FNU1. Clearing is seen at the highest concentrations with individual plaques discernible at subsequent dilutions. Each single plaque is ≈1 mm diameter. (**B**) TEM image of FNU1 revealing *Siphoviridae* bacteriophage with long ≈310 nm tail and icosahedral head diameter of ≈88 nm.

Genomic analysis {#Sec14}
----------------

Bacteriophage DNA extraction and sequencing was performed on three separate occasions. On all occasions, a single contig of 130914 bp was obtained with coverage ranging from 121 to 2400 times. The process was repeated to ensure accuracy and because the sequence generated displayed low homology to any known bacteriophage or other genomes present in the database. The FNU1 bacteriophage genome (NCBI Genbank Accession Number: MK554696) was composed of 178 predicted ORFs of which 30.34% (54/178) had no significant homology to any sequences in the Genbank database and 38.20% (68/178) had some similarity but with E values of less than 1e-4. Of the remaining genome for bacteriophage FNU1, 31.46% (56/178 ORFs) had significant homology to other sequences, and of these, 71.43% (40/56 ORFs) had conserved domains. The overall GC content was 25.0%. The ORFs, their significant matches and E values are shown in Table [1](#Tab1){ref-type="table"}.Table 1Putative FNU1 proteins and their homology to published sequences.ORFCoordinatesSize (aa)Homology to known sequences in NCBI database% Identity% Query coverE0 valueORF11..1659553Gifsy-2 prophage tail fiber protein, partial \[*Salmonella enterica* subsp. *enterica* serovar Newport str. SHSN010\]5591.00E − 06ORF21770..2267166No significant similarity foundORF32264..246467No significant similarity foundORF42457..2855133Hybrid sensor histidine kinase/response regulator \[*Pedobacter heparinus*\]47289.40E + 00ORF52857..3399181No significant similarity foundORF63396..4223276Nucleotidyltransferase domain-containing protein \[*Balneola* sp.\]35922.00E − 29ORF74217..4948244Hypothetical protein \[*Bacillus* sp.\]35972.00E − 35ORF84950..5366139ComF family protein \[*Yoonia litorea*\]31388.30E − 01ORF95575..579674rfaE bifunctional protein \[*Desulfurobacterium thermolithotrophum* DSM 11699\]27607.60E − 01ORF105884..6558225Hypothetical protein \[*Staphylococcus xylosus*\]40912.00E − 41ORF116577..7395273Antirepressor \[*Fusobacterium necrophorum*\]39977.00E − 44ORF128220..8831204Hypothetical protein \[*Olleya sp*. VCSM12\]30588.40E + 00ORF138835..9557241No significant similarity foundORF149557..11392612Hypothetical protein DRJ01_10315, partial \[*Bacteroidetes bacterium*\]28775.00E − 41ORF1511402..12949516Hypothetical protein DRJ01_10320 \[*Bacteroidetes bacterium*\]29961.00E − 41ORF1613878..14297140Methyl-CpG-binding domain-containing protein 9 \[*Cicer arietinum*\]27737.40E + 00ORF1714397..15473359No significant similarity foundORF1815775..1607199No significant similarity foundORF1916073..16444124Myosin-IB-like \[*Plutella xylostella*\]31508.50E + 00ORF2016437..16991185Hypothetical protein UU59_C0024G0011 \[candidate division WWE3 bacterium GW2011_GWE1_41_27\]26891.00E + 00ORF2116988..17623212No significant similarity foundORF2217665..18798378Type I secretion system permease/ATPase \[*Mesorhizobium sp*. WSM4313\]44163.30E + 00ORF2318866..19642259No significant similarity foundORF2419639..20283215No significant similarity foundORF2520293..262171975Phage tail tape measure protein, TP901 family, core region \[*Cetobacterium ceti*\]24264.00E − 20ORF2626279..27295339Hypothetical protein \[*Brevibacillus fluminis*\]43127.90E + 00ORF2727390..28244285Hypothetical protein \[*Fusobacterium periodonticum*\]42704.00E − 31ORF2828300..28674125No significant similarity foundORF2929187..325761130DUF1983 domain-containing protein \[*Rhizobium subbaraonis*\]26133.00E − 05ORF3033217..34371385Transposase \[*Fusobacterium sp*. CM1\]84970.00E + 00ORF3134498..35637380Hypothetical protein \[*Cetobacterium sp*. ZWU0022\]41431.00E − 26ORF3235640..36641334No significant similarity foundORF3336653..37438262Hypothetical protein AKJ51_02780 \[candidate divison MSBL1 archaeon SCGC-AAA382A20\]25292.70E + 00ORF3437551..38327259ATP/GTP-binding protein \[*Streptococcus parasanguinis*\]37965.00E − 26ORF3538303..38713137No significant similarity foundORF3639575..39889105Anaerobic ribonucleoside-triphosphate reductase \[*Fusobacterium perfoetens*\]44903.00E − 18ORF3741026..4124774No significant similarity foundORF38(41608..41883)92No significant similarity foundORF39(42013..42279)89Homoserine kinase \[*Fusobacterium* sp. CM1\]47478.60E + 00ORF40(42455..42775)107No significant similarity foundORF41(43304..43540)79No significant similarity foundORF42(44438..44680)81Serine--tRNA ligase \[*Candidatus Daviesbacteria* bacterium RIFCSPHIGHO2_01_FULL_37_27\]40537.40E + 00ORF43(44816..45196)127Hypothetical protein \[*Lactobacillus reuteri*\]48522.00E − 11ORF44(45315..45611)99Hypothetical protein \[uncultured Mediterranean phage uvMED\]42659.00E − 03ORF45(46128..46544)139No significant similarity foundORF46(46574..46885)104No significant similarity foundORF47(46903..47127)75Hypothetical protein J132_07476 \[*Termitomyces* sp. J132\]37656.20E + 00ORF48(47138..47506)123Alkaline phosphatase \[*Stackebrandtia nassauensis*\]23759.20E + 00ORF49(47521..47745)75No significant similarity foundORF50(48158..48322)54No significant similarity foundORF51(48727..49209)161Anaerobic ribonucleoside-triphosphate reductase activating protein \[*Fusobacterium* sp.\]51912.00E − 50ORF52(49458..49658)67No significant similarity found.ORF53(49670..49996)108Hypothetical protein DV735_g31 \[*Chaetothyriales* sp. CBS 134920\]36717.50E − 01ORF54(50006..50467)154No significant similarity foundORF55(50467..50955)163No significant similarity foundORF56(51137..52471)445Anaerobic ribonucleoside-triphosphate reductase \[*Fusobacterium perfoetens*\]53983.00E − 167ORF57(52800..53834)345GIY-YIG nuclease family protein \[*Clostridioides difficile*\]42551.00E − 35ORF58(53905..54813)303Anaerobic ribonucleoside-triphosphate reductase \[*Fusobacterium varium*\]46981.00E − 71ORF59(54800.55060)87Hypothetical protein OFPII_09960 \[*Osedax symbiont* Rs1\]38518.30E − 01ORF60(55064..55387)108No significant similarity foundORF61(55384..55851)156No significant similarity foundORF62(56004..56456)151No significant similarity foundORF63(56485..56724)80Mitochondrial carrier homolog 2 \[*Drosophila arizonae*\]40538.50E + 00ORF64(56733..56978)82Glycosyltransferase \[*Algoriphagus resistens*\]36598.10E − 01ORF65(56985..57296)104No significant similarity foundORF66(57298..57597)100No significant similarity foundORF67(58609..58989)127Outer membrane protein assembly factor BamA \[*Sutterella parvirubra*\]27623.40E + 00ORF68(59003..59752)250Hypothetical protein \[*Fusobacterium nucleatum*\]33311.70E − 02ORF69(59754..60326)191Hypothetical protein \[*Fusobacterium periodonticum*\]37328.60E − 01ORF70(60323..60697)125No significant similarity foundORF71(60676..60894)73ATP-dependent DNA ligase \[*Rhizophagus irregularis*\]37675.90E + 00ORF72(60916..61179)88Hypothetical protein \[*Desulfobacula toluolica*\]26705.60E − 01ORF73(61184..61369)62No significant similarity foundORF74(61359..61799)147Hypothetical protein SAMN05444672_10818 \[*Bacillus* sp. OK838\]50282.40E + 00ORF75(61796..62185)62No significant similarity foundORF76(62176..62544)123No significant similarity foundORF77(62560..63000)147No significant similarity foundORF78(63013..63480)156Molecular chaperone DnaJ \[*Paenibacillus* sp. Soil724D2\]32912.00E − 19ORF79(63778..64101)108DUF1874 domain-containing protein \[*Defluviitalea phaphyphila*\]57972.00E − 31ORF80(64133..64306)58Hypothetical protein HMPREF1127_1046 \[*Fusobacterium necrophorum subsp. funduliforme* Fnf 1007\]49821.00E − 07ORF81(64450..64671)74DNA segregation ATPase FtsK/SpoIIIE, S-DNA-T family \[*Crenotalea thermophila*\]45567.10E + 00ORF82(64738..65517)260Radical SAM protein \[*Clostridium botulinum*\]49945.00E − 79ORF83(65598..68396)933Hypothetical protein \[*Fusobacterium necrophorum*\]3668.80E − 01ORF84(68490..68984)165Hypothetical protein \[*Fusobacterium hwasookii*\]41886.00E − 32ORF85(68984..69172)63Hypothetical protein \[*Fusobacterium periodonticum*\]68983.00E − 22ORF86(69291..69605)105Hypothetical protein YYE_03786 \[*Plasmodium vinckei vinckei*\]36625.20E − 01ORF87(69589..69942)118Na + /H + antiporter \[*Porphyromonas* sp. oral taxon 279\]26733.40E + 00ORF88(69911..70651)247No significant similarity foundORF89(70663..71040)126Hypothetical protein \[*Lactobacillus* sp. CBA3605\]33415.30E + 00ORF90(71042..71473)144Guanylate-binding protein 6-like \[*Eptesicus fuscus*\]37482.90E − 01ORF91(71466..71660)65Hypothetical protein \[*Rhodopirellula* sp. SWK7\]43641.40E + 00ORF92(71647..71922)92Tyrosine recombinase XerC \[*Chloracidobacterium thermophilum*\]41478.60E + 00ORF93(72047..72946)300No significant similarity foundORF94(73058..73651)198Hypothetical protein CTER_0441 \[*Ruminiclostridium cellobioparum* subsp. *termitidis* CT1112\]33435.50E + 00ORF95(73706..76168)821Polymerase protein \[candidate division WWE3 bacterium GW2011_GWC2_44_9\]30373.00E − 28ORF96(76155..77018)288Guanylate kinase \[*Emticicia* sp. MM\]39626.00E − 24ORF97(77327..78076)250MerR family transcriptional regulator \[*Bacillus* sp. EB01\]23541.50E + 00ORF98(78095..78961)289Fic family protein \[*Fusobacterium nucleatum*\]38668.00E − 30ORF99(78937..79356)140Hypothetical protein BpsS36_00041 \[*Bacillus phage* vB_BpsS-36\]42946.00E − 18ORF100(79396..79920)175Siphovirus Gp157 family protein \[*Fusobacterium nucleatum*\]51893.00E − 39ORF101(79933..80406)158No significant similarity foundORF102(80372..80731)120Hypothetical protein TBLA_0I01080 \[*Tetrapisispora blattae* CBS 6284\]31669.50E + 00ORF103(80744..81175)144O-acetyl-ADP-ribose deacetylase 1-like \[*Branchiostoma belcheri*\]44983.00E − 36ORF104(81177..81731)185Hypothetical protein \[*Clostridium botulinum*\]34961.00E − 20ORF105(81819..82436)206Hypothetical protein \[*Fusobacterium nucleatum*\]32832.00E − 13ORF106(82601..83236)212Hypothetical protein \[*Clostridium sp*. 12(A)\]49857.00E − 53ORF107(83330..84430)367DNA cytosine methyltransferase \[*Methanobrevibacter ruminantium*\]31989.00E − 57ORF108(84452..84640)63No significant similarity foundORF109(84691..86247)519Hypothetical protein FUSO4_11650 \[*Fusobacterium necrophorum* DJ-1\]49977.00E − 166ORF110(86400..86783)128Isovaleryl-CoA dehydrogenase \[*Erythrobacter gangjinensis*\]40501.30E − 01ORF111(86773..87030)86Hypothetical protein ABS80_03590 \[*Pseudonocardia sp*. SCN 72--51\]33606.20E − 01ORF112(87053..88336)428ATP dependent DNA ligase domain protein \[*Clostridioides difficile*\]37972.00E − 67ORF113(88329..88946)206VP1 protein, partial \[Coxsackievirus A16\]33231.70E + 00ORF114(88947..89186)80No significant similarity foundORF115(89161..89643)161DNA repair protein MmcB-related protein \[*Fusobacterium*\]30881.00E − 15ORF116(89640..89858)73No significant similarity foundORF117(89842..90486)215Hypothetical protein \[*Fusobacterium necrophorum*\]45801.00E − 41ORF118(90575..91204)210Hypothetical protein \[*Adhaeribacter aquaticus*\]25594.30E + 00ORF119(91309..92733)475Hypothetical protein \[Ralstonia phage RSP15\]27672.00E − 25ORF120(92743..93252)170dUTP diphosphatase \[*Clostridium bartlettii* CAG:1329\]41995.00E − 28ORF121(93249..94526)426Hypothetical protein \[*Bacillus endophyticus*\]24738.00E − 26ORF122(94529..95317)263ORF6N domain-containing protein \[*Fusobacterium nucleatum*\]43775.00E − 44ORF123(95417..96418)334DNA primase (bacterial type) \[*Chlamydia trachomatis*\]39501.00E − 18ORF124(96431..97912)494DNA helicase \[*Clostridium botulinum*\]29544.00E − 25ORF125(97909..98334)142epsC Polysaccharide biosynthesis protein, protein-tyrosine-phosphatase \[*Lactococcus lactis* subsp. *lactis*\]33521.90E + 00ORF126(98404..99702)432No significant similarity foundORF127(99709..100146)146Phage antirepressor \[*Clostridium innocuum*\]41794.00E − 22ORF128(100272..100976)235ATP-binding protein \[*Peptoniphilus obesi*\]37912.00E − 38ORF129(100986..101510)175Hypothetical protein DLH72_04485 \[*Candidatus Gracilibacteria* bacterium\]36964.00E − 17ORF130(101497..101679)61No significant similarity foundORF131(101885..102676)264DNA adenine methylase \[*Ruminococcus albus*\]39923.00E − 41ORF132(102741..103346)202Ribonuclease HI \[*Fusobacterium russii*\]53991.00E − 63ORF133(103346..103561)72No significant similarity foundORF134(103545..103769)75Hypothetical protein K457DRAFT_16159 \[*Mortierella elongata* AG-77\]40466.00E + 00ORF135(103871..104125)85No significant similarity foundORF136(104118..104633)172Hypothetical protein \[*Selenomonas bovis*\]52255.00E − 04ORF137(104773..104997)75Multidrug efflux RND transporter permease subunit \[*Motiliproteus coralliicola*\]30985.50E + 00ORF138(104997..105212)72Peptide ABC transporter substrate-binding protein \[*Vibrio gangliei*\]38614.80E + 00ORF139(105199..105858)220Transcriptional regulator, TetR family \[*Clostridium sp*. MSTE9\]30371.60E + 00ORF140(105871..106029)53Hypothetical protein L915_04856, partial \[*Phytophthora parasitica*\]46492.60E + 00ORF141(106133..106942)270Prohibitin family protein \[*Fusobacterium periodonticum*\]77993.00E − 150ORF142(106942..107316)125Hypothetical protein \[*Fusobacterium necrophorum*\]48371.40E + 00ORF143(107317..107580)88Type II toxin-antitoxin system HipA family toxin \[*Prevotella sp*. ICM33\]29755.20E + 00ORF144(107584..108336)251Hypothetical protein \[*Corynebacterium matruchotii*\]52982.00E − 89ORF145(108336..108842)169Hypothetical protein \[*Fusobacterium nucleatum*\]50331.00E − 06ORF146(108939..109391)151Furin-1 precursor \[*Schistosoma japonicum*\]32539.00E − 02ORF147(109396..109905)170No significant similarity foundORF148(109906..110742)279Bifunctional methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase \[*Agrococcus casei*\]29973.00E − 13ORF149(110730..111284)185Hypothetical protein A2Y22_00670 \[*Clostridiales* bacterium GWD2_32_59\]27745.00E + 00ORF150(111332..111955)208TPA: tRNA (adenine-N(6)-)-methyltransferase \[*Candidatus Gastranaerophilales* bacterium HUM_13\]39923.00E − 40ORF151(112023..114062)680AAA family ATPase \[*Pseudodesulfovibrio profundus*\]28754.00E − 29ORF152(114111..115580)490Hypothetical protein \[*Clostridium botulinum*\]37851.00E − 69ORF153115966..11614861No significant similarity foundORF154116254..116772173No significant similarity foundORF155116783..117202140No significant similarity foundORF156117202..117636145Heparinase \[*Paenibacillus macerans*\]33374.20E + 00ORF157117630..11781261No significant similarity foundORF158117915..11814276No significant similarity foundORF159118123..119262380Hypothetical protein \[*Fusobacterium mortiferum*\]68314.00E − 40ORF160119268..119579104Glycosyltransferase \[*Kingella kingae*\]35627.00E + 00ORF161119675..119983103Hypothetical protein \[*Streptococcus sobrinus*\]35865.00E − 15ORF162119997..120386130Hypothetical protein \[*Streptococcus oralis*\]32463.20E − 02ORF163120534..120965144Hypothetical protein \[*Fusobacterium periodonticum*\]33843.00E − 10ORF164120975..121694240No significant similarity foundORF165121708..122073122TonB-dependent receptor \[*Mucilaginibacter* sp. OK098\]31873.70E + 00ORF166122070..124286739Metallophosphoesterase \[*Leptotrichia hofstadii*\]49990.00E + 00ORF167124339..12451860No significant similarity foundORF168125623..12584173No significant similarity foundORF169125880..12611980Glutaredoxin \[*Fusobacterium nucleatum* subsp. *nucleatum*\]56788.00E − 17ORF170126477..12665660No significant similarity foundORF171126614..12690196HU family DNA-binding protein \[*Neisseria weaveri*\]44935.00E − 17ORF172127245..128036264ORF6N domain-containing protein \[*Fusobacterium necrophorum*\]73463.00E − 58ORF173128097..12827359No significant similarity foundORF174128354..129103250Hypothetical protein CANCADRAFT_31211 \[*Tortispora caseinolytica* NRRL Y-17796\]33239.00E + 00ORF175129197..129547117DUF1353 domain-containing protein \[*Fusobacterium necrophorum*\]47766.00E − 21ORF176129564..129980139Hypothetical protein \[*Fusobacterium necrophorum*\]39902.00E − 23ORF177129980..130537186N-acetylmuramoyl-L-alanine amidase \[*Fusobacterium necrophorum*\]44951.00E − 36ORF178130553..130858102Hypothetical protein \[*Aeromonas enteropelogenes*\]40501.40E + 00

Functional genomics predictions were mapped using the Geneious software 11.0.5 (Fig. [2](#Fig2){ref-type="fig"}) with putative structural genes (pink), putative DNA manipulation genes (green), putative regulatory genes (blue), putative lytic genes (red) and hypothetical genes (yellow) marked. Although the majority of genes couldn't be assigned functionality, a pattern of clustering of related genes was observed (Fig. [2](#Fig2){ref-type="fig"}). Putative structural genes appeared to be orientated in a clockwise direction while the rest were orientated anticlockwise. The putative structural genes were interspaced with putative lysis and regulatory genes, as well as other genes that have no known functionality or homology located between sites 1 and 40000 bp in the genome map (Fig. [2](#Fig2){ref-type="fig"}). The genes in anticlockwise orientation were comprised mostly of putative DNA manipulation genes located between sites 65000 and 130000 bp in the genome map (Fig. [2](#Fig2){ref-type="fig"}) that may be involved in the infection and packaging processes, as well as a cluster of putative lysis genes (located between 45000 and 55000 bp).Figure 2FNU1 functional genome map with putative structural genes (pink), putative DNA manipulation genes (green), putative regulatory genes (blue), putative lytic genes (red) and hypothetical genes (yellow) marked. Although majority of genes couldn't be assigned functionality, a pattern of clustering of related genes was observed. Genes in anticlockwise orientation were comprised mostly of putative DNA manipulation genes (between 65000 and 130000 bp and possibly involved in infection & packaging), as well as cluster of putative lysis genes (between 45000 and 55000 bp).

tRNAs and tmRNAs in the *F. nucleatum* bacteriophage FNU1 genome {#Sec15}
----------------------------------------------------------------

There were six putative tRNAs identified using ARAGON and tRNAscan-SE 2.0. These included five that did not have any introns and one with a C-loop intron. The tRNA with a C-loop intron was a histidine-tRNA of 74 bp and GC content of 43.2%. The other five introns included an isoleucine-tRNA (91 bp, GC = 36.3%), a proline-tRNA (76 bp, GC = 47.4%), a serine-tRNA (87 bp, GC = 43.7%), a tyrosine-tRNA (89 bp, GC = 40.4%) and a cysteine-tRNA (74 bp, GC = 37.8). All introns were in a single cluster located at 44553 bp to 45210 bp in the genome (Fig. [2](#Fig2){ref-type="fig"}). No tmRNA genes were found in the FNU1 genome sequence.

Putative bacteriophage FNU1 defence against bacterial anti-phage systems {#Sec16}
------------------------------------------------------------------------

Conserved protein family (Pfam) prediction on BLASTp analysis indicated there were 13 ORFs with predicted Pfam domains that may be involved in bacteriophage FNU1 evading host immunity (Table [2](#Tab2){ref-type="table"}). These included at least three genes each putatively encoding antirepressors, methylation genes and toxin-antitoxin systems. According to the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) database (<http://crispr.i2bc.paris-saclay.fr/>)^[@CR36]^, no CRISPR regions were found in the phage FNU1 genome.Table 2Putative phage defence mechanisms against bacterial anti-phage immunity.ORFCoordinatesProtein familyPfamE- valueFunctionORF105884..6558Phage regulatory protein Rha (Phage_pRha) (N-terminal)096692.95E-22Phage regulatory proteins usually found in temperate phages and bacterial prophage regions and include rha genes that interfere with bacterial infection in strains that lack integration host factor \[52\]ORF105884..6558ORF6C domain (C-terminal)105521.14E-13Antirepressor protein \[52\]ORF116577..7395Phage antirepressor protein KilAC domain033749.63E-29Antirepressor protein \[52\]ORF2727390..28244Phage antirepressor protein KilAC domain033748.61E-18Antirepressor protein \[52\]ORF3437551..38327AAA domain, putative AbiEii toxin133047.61E-05Type IV toxin antitoxin system that may be part of the abortive phage resistance TA system \[53\]ORF82(64738..65517)Radical SAM superfamily040552.25E-09Radical SAM proteins catalyse different reactions from unusual methylations, isomerisation, sulphur insertion, ring formation, anaerobic oxidation and protein radical formation\[54\]ORF98(78095..78961)Fic/DOC family026615.54E-11This family consists of the Fic (Filamentation Induced by cAMP) protein and DOC (death on curing) proteins. The Fic protein is involved in the regulation of cell division via folate metabolism. DOC will cure bacterial cells of prophage and also target protein synthesis machinery and inducing a reversible growth arrest. This arrest can be reversed by its antitoxin partner Phd (prevents host death) \[55\]ORF100(79396..79920)Siphovirus Gp157055651.79E-33Bacteria that contain genes coding siphovirus GP157, a protein of *Streptococcus thermophiles* SFi phages are thought to have an increased resistance to phage infection\[56\]ORF107(83330..84430)C-5 cytosine-specific DNA methylase001454.45E-49These enzymes specifically methylate the C-5 carbon of cytosines in DNA to produce C5-methylcytosine \[57\]ORF127(99709..100146)Phage antirepressor protein KilAC domain033743.69E-07An antirepressor protein\[52\]ORF131(101885..102676)D12 class N6 adenine-specific DNA methyltransferase020865.16E-04These enzymes will specifically methylate the amino group at the C-6 position of adenines in DNA \[58\]ORF132(102741..103346)Caulimovirus viroplasmin (N - Terminal)016933.89E-04These form the main components of viral inclusion bodies where viral assembly, DNA synthesis and accumulation takes place \[59\]ORF159118123..119262Phage regulatory protein Rha (Phage_pRha) (N-terminal)096692.28E-04Phage regulatory proteins that are usually found in temperate phages and bacterial prophage regions and include rha gens that interferes with bacterial infection in strains that lack integration host factor.\[52\]ORF159118123..119262Phage antirepressor protein KilAC domain (C - Terminal)033742.68E-15Antirepressor protein \[52\].ORF172127245..128036ORF6N domain (N-terminal)105431.23E-16Antirepressor protein \[52\].ORF172127245..128036Phage antirepressor protein KilAC domain (C - Terminal)033741.52E-18Antirepressor protein \[52\].

Phylogenetic relatedness with other bacteriophage targeting oral bacteria {#Sec17}
-------------------------------------------------------------------------

The genome of bacteriophage FNU1 showed little homology to any bacteriophage deposited in NCBI Genbank. To understand the relatedness of FNU1 to other bacteriophages, a phylogenetic tree was constructed. Whole genomes of bacteriophages targeting oral bacteria were downloaded from NCBI Genbank and compared with FNU1 as they are found in the same microenvironment. Bacteriophage FNU1 was found to be most closely related to *Streptococcus mutans* and *Streptococcus* spp. bacteriophages (Fig. [3](#Fig3){ref-type="fig"}). The only *F. nucleatum* bacteriophage genome in the database is the prophage ΦFunu1, which is phylogenetically distant from FNU1, sharing very little genetic homology. ΦFunu1 branches off earlier in the phylogenetic tree and is most closely related to P1, a bacteriophage for *Lactobacillus plantarum* and the bacteriophage ΦEf11 for *Enterococcus faecalis* (Fig. [3](#Fig3){ref-type="fig"}).Figure 3Phylogenetic analysis of FNU1 in relation to other bacteriophages associated with oral bacteria. FNU1 was most closely related to *Streptococcus mutans* and other *Streptococcu*s spp. bacteriophages.

Effect of bacteriophage FNU1 on *F. nucleatum* biofilm mass {#Sec18}
-----------------------------------------------------------

To evaluate the potential application of bacteriophage FNU1 in the treatment of gastro-intestinal biofilms, a biofilm model of *F. nucleatum* was generated as described above. The median \[Inter-Quartile Range (IQR)\] absorbance at OD~600~ of the biofilm without bacteriophage treatment was 2.17 (1.81--2.21). This was significantly higher (p \< 0.001) than that following FNU1 bacteriophage treatment for 24 h, where median (IQR) was 0.76 (0.71--0.89), or 35% of the untreated value (Fig. [4](#Fig4){ref-type="fig"}). The bacteriophage treated biofilm had a significantly higher absorbance (p \< 0.001) compared to the negative control (no bacteria control): median (IQR) absorbance at OD~600~ of the negative control was 0.14 (0.14--0.15) (Fig. [4](#Fig4){ref-type="fig"}). Subtracting absorbance readings for the negative control (0.14) from both the treated (0.76) and untreated (2.17) biofilms results in untreated biofilms having an OD of 2.03 and treated biofilms having an OD of 0.62. Therefore, FNU1 phage treatment results in a 70% reduction in *F. nucleatum* biomass.Figure 4Significant reduction of *Fusobacterium nucleatum* biofilm treated with FNU1 bacteriophage.

Viability of the *F. nucleatum* biofilm after treatment with bacteriophage FNU1 {#Sec19}
-------------------------------------------------------------------------------

To evaluate the viability of *F. nucleatum* in the biofilms following treatment with bacteriophage FNU1, live/dead staining using SYBR® gold and propidium iodide was applied to biofilms formed on microscope slides and imaged using confocal microscopy. The untreated biofilm had predominantly green fluorescent cells, indicating structurally intact membranes. The bacteriophage treated biofilm showed few cells, most of which were red/yellow, indicating structurally compromised membranes, and only very few cells with intact membranes (green) in clumps (Fig. [5](#Fig5){ref-type="fig"}).Figure 5Confocal images of SYBR® gold and propidium iodide staining following FNU1 bacteriophage treated (**A**) and untreated (**B**) *Fusobacterium nucleatum* biofilm.

Discussion {#Sec20}
==========

The novel bacteriophage FNU1 genome is over 130 kb in length and displays little homology to other known viral genomes. Because of this, it is difficult to describe any potential synteny between FNU1 and other bacteriophage genomes, although organisational similarity to some of the more abundant bacteriophages found in the human gut exists, where the structural and infection/packaging genes are in opposite orientation to each other^[@CR37]^. The relatively large genome and structure of the virus, with a capsid of approximately 90 nm diameter and tail of over 300 nm in length, may have contributed to the fact that it was only able to produce clear discernible plaques when the concentration of agar it was grown on was reduced from 1.5% to 1%. The presence of several tRNAs in the FNU1 genome may indicate the requirement for additional translational mechanisms to complement those provided by the host cell. In its phylogeny, bacteriophage FNU1 clusters more closely to several bacteriophages against the oral pathogen *S. mutans*, and distantly from the only *F. nucleatum* bacteriophage in the database, the prophage ΦFunu1.

FNU1 has almost 8% of its ORFs devoted to putative defence against bacterial anti-bacteriophage systems, with several genes each coding for putative antirepressors, methylation genes to avoid restriction modification and toxin-antitoxin mechanisms that may prevent abortive infections. While some bacteriophages such as *Vibrio cholerae* ICP1 are known to carry CRISPR sequences which may contribute to their virulence^[@CR38]^, the FNU1 genome had no such recognisable regions. All the *F. nucleatum* strains in the CRISPR database (<http://crispr.i2bc.paris-saclay.fr/>)^[@CR36]^ have one CRISPR with the number of spacers ranging from 3 to 52, (average approximately 25 spacers). *Porphyromonas gingivalis*, the major etiologic agent associated with chronic periodontitis, and for which no lytic bacteriophage has yet been isolated, has very extensive CRISPR immune mechanisms^[@CR39],[@CR40]^. Each *P. gingivalis* strain in the database has more than one confirmed CRISPR locus (some with a maximum of five), with the total number of spacers in each bacterial strain ranging from 14 to 136 (<http://crispr.i2bc.paris-saclay.fr/>). This contrasts with *C. acnes* strains, where none have a confirmed CRISPR locus, (although some are denoted as having possible CRISPR regions based on the database's algorithms, filtering sequence length, matching repeats and amount of successive repeats)^[@CR36]^, and against which there are over 80 reported bacteriophages^[@CR41]^.

In this report, we demonstrate the capacity for FNU1 to disrupt established *F. nucleatum* biofilms. Our results show the capacity of FNU1 to effectively kill cells within a *F. nucleatum* biofilm, and although not as complex as polymicrobial biofilms shown to develop during periodontitis^[@CR8],[@CR29],[@CR42]^, this work suggests that FNU1 has potential for application in more complex systems. *F. nucleatum* is one of the late colonisers in oral polymicrobial biofilms. Its capacity to co-aggregate intergenerically with representatives of all oral bacterial species^[@CR8]^ indicates it provides the necessary scaffolding for these communities to grow, develop and flourish synergistically. We have previously shown that diverse bacteriophages are able to be formulated into dosage forms such as lozenges and pastes, and subsequently released to kill underlying bacteria *in-vitro*^[@CR43]^. Both of these dosage forms would provide very useful strategies for delivery of bacteriophage such as FNU1 for testing in the treatment of periodontitis and other diseases associated with *F. nucleatum*, as they allow slower "release" of bacteriophage into the oral cavity, and in the case of toothpastes, can be used to gently massage the bacteriophage onto the tooth and gum surface.

Finally, *F. nucleatum* has recently been described as an oncobacterium, associated with a range of human cancers^[@CR4]^. The organism has a causal role in tumorigenesis^[@CR12]^ and also confers resistance to chemotherapy^[@CR13]^. In their animal model, Bullman S. *et al*. demonstrated that treatment with metronidazole, an antibiotic that their *F. nucleatum* strains were sensitive to, reduced cancer cell proliferation and tumour growth. However, this approach of using antibiotics to kill *Fusobacterium* may be unsuitable clinically, as it has been previously demonstrated that perturbation of microbiota by antibiotics leads to reduced efficacy of chemoimmunotherapy for a range of cancers, including colorectal cancer^[@CR44],[@CR45]^. On the other hand, the discovery of FNU1, with capacity to disrupt *F. nucleatum* biofilms, represents a potentially feasible means of targeted removal of this bacteria for microbiota manipulation in colorectal cancer management. In addition, while it has been suggested that bacteriophages in the gut virome may alter the microbiome such that *F. nucleatum* is able to overgrow and facilitate neoplasia in colon cells^[@CR46]^, bacteriophages such as FNU1 may assist in overcoming such dysbiosis. That bacteriophages can be successfully formulated into suppositories, as we have previously shown^[@CR32]^, may assist in delivery.

In conclusion, this work describes the first full genome sequence and functional characterisation of a novel lytic bacteriophage against *F. nucleatum*, a bacterium associated with periodontitis as well as cancers of the GI tract such as colon cancer. FNU1 is unique in that it shares very little homology with other known bacteriophages. Functionally, FNU1 is capable of breaking down *F. nucleatum* biofilms and lysing the bacterial cells composing the biofilm. This bacteriophage, then, is able to be tested in more complex oral biofilm assays and could potentially be tested *in-vivo* to assess capacity to treat periodontitis, as well as possibly assist in colon cancer treatment, following formulation in appropriate dosage forms.
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